HomeIMMP • NASDAQ
Immutep Ltd - ADR
$1.94
After Hours:
$1.93
(0.49%)-0.0096
Closed: Jan 27, 5:25:43 PM GMT-5 · USD · NASDAQ · Disclaimer
US listed security
Previous close
$1.97
Day range
$1.90 - $1.97
Year range
$1.66 - $3.34
Market cap
297.30M USD
Avg Volume
127.17K
Financials
Income Statement
Revenue
Net income
(AUD)Jun 2024Y/Y change
Revenue
865.57K-4.89%
Operating expense
2.03M-10.92%
Net income
-10.74M-11.49%
Net profit margin
-1.24K-17.23%
Earnings per share
——
EBITDA
-11.21M-17.52%
Effective tax rate
——
Total assets
Total liabilities
(AUD)Jun 2024Y/Y change
Cash and short-term investments
181.88M47.37%
Total assets
201.58M36.71%
Total liabilities
12.06M9.82%
Total equity
189.52M—
Shares outstanding
1.45B—
Price to book
15.12—
Return on assets
-14.53%—
Return on capital
-15.32%—
Net change in cash
(AUD)Jun 2024Y/Y change
Net income
-10.74M-11.49%
Cash from operations
-8.19M30.16%
Cash from investing
-10.30M-87,445.92%
Cash from financing
47.81M25.58%
Net change in cash
29.03M5.47%
Free cash flow
-6.10M-44.31%
About
Immutep Ltd is a biotechnology company working primarily in the field of cancer immunotherapy using the LAG3 immune control mechanism. The company was originally built on CVac, a therapeutic cancer vaccine. In late 2014 the privately held French immunotherapy company Immutep SA was purchased by Prima Biotech. Prima currently has three main products in its pipeline, all acquired with Immutep: Eftilagimod alpha, which is recombinant soluble LAG-3, used as an activator of antigen presenting cells. This product has completed a Phase IIa clinical study, where it doubled the expected response rate in HER2-negative metastatic breast cancer. IMP731, a depleting monoclonal antibody for autoimmune diseases, targeting LAG-3+ activated T cells. This antibody has been licensed to GlaxoSmithKline. IMP701, an antagonist monoclonal antibody to LAG3 for use in cancer. This product has been licensed to Novartis Wikipedia
Founded
2001
Employees
19
Search
Clear search
Close search
Google apps
Main menu